Covista 50 Tablet

About Covista 50 24 mg + 26 mg Tablet

The tablet Covista 50 contains Sacubitril + Valsartan and is made by Advanced Chemical Industries PLC. Only a doctor can decide if this medicine is suitable for a particular person.

There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. 2 of them have a lower unit price than Covista 50. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.

What is Covista 50 24 mg + 26 mg Tablet?

The tablet Covista 50 contains Sacubitril + Valsartan and is made by Advanced Chemical Industries PLC. It is used to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. The dose is decided by the doctor based on the patient's condition and tolerance. Whether it suits you is a decision for your doctor.

Uses of Covista 50

Only a doctor can decide if this medicine is suitable for a particular person. This medicine is not for treating high blood pressure or any other condition unless prescribed by a doctor. It helps lower the risk of dying from heart problems and reduces the chance of needing hospital care for heart failure. Your doctor will decide if it is suitable for you.

How to use Covista 50

Swallow the tablet as directed by your doctor. Swallow the tablet with water. Covista 50 is taken by mouth. If you are unsure how to take it, ask your doctor or pharmacist. The doctor decides the dose and how often you take it, including any change in dose over time. Do not stop or change the dose on your own, even if you feel better, because heart failure treatment works over time.

Side effects of Covista 50

The doctor will check kidney function and potassium levels during treatment. Do not ignore severe symptoms. Get urgent medical help if you notice swelling of the face, lips, tongue or throat, or trouble breathing, as these may be signs of angioedema. Tell your doctor if you feel very dizzy or faint, or pass much less urine than usual. Tell your doctor if you notice any side effects or if they bother you.

Safety and precautions

Do not use Covista 50 if you are allergic to any of its ingredients, or if you have had angioedema related to an ACE inhibitor or an ARB, or have hereditary angioedema. Pregnancy and breastfeeding: ask the doctor before use.

Frequently asked questions

What is Covista 50 used for?

Only a doctor can decide if this medicine is suitable for a particular person. This medicine is not for treating high blood pressure or any other condition unless prescribed by a doctor.

How do I use Covista 50 correctly?

Swallow the tablet as directed by your doctor. Swallow the tablet with water.

What are the side effects of Covista 50?

The doctor will check kidney function and potassium levels during treatment. Do not ignore severe symptoms.

Is Covista 50 safe for everyone?

Do not use Covista 50 if you are allergic to any of its ingredients, or if you have had angioedema related to an ACE inhibitor or an ARB, or have hereditary angioedema. Pregnancy and breastfeeding: ask the doctor before use.

Indications

This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • ... Read more
This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.

Pharmacology

This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.

Dosage & Administration

Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.

Reduce the starting dose to 24/26 mg twice daily for:
  • Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
  • Patients with severe renal impairment.
  • Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.

Recommended Dose Titration-

Pediatric Patients Less than 40 kg:
  • Starting: 1.6 mg/kg
  • Second: 2.3 mg/kg
  • Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
  • Starting: 24/26 mg
  • Second: 49/51 mg
  • Final: 49/51 mg
Pediatric Patients At least 50 kg:
  • Starting: 49/51 mg
  • Second: 72/78 mg
  • Final: 97/103 mg

Interaction

Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.

Contraindications

This combination is contraindicated:
  • In patients with hypersensitivity to any component
  • In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy 
  • With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor 
  • With concomitant use of aliskiren in patients with diabetes

Side Effects

The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.

Pregnancy & Lactation

Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.

Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
 
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.

Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.

Precautions & Warnings

This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.

This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.

Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.

Overdose Effects

Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.

Storage Conditions

Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.

Alternative brands of Sacubitril + Valsartan

Other brands with the same generic name, cheapest first.

See all 25 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.